Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sturton, G.
Right arrow Articles by Fitzgerald, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sturton, G.
Right arrow Articles by Fitzgerald, M.
(Chest. 2002;121:192S-196S.)
© 2002 American College of Chest Physicians

Phosphodiesterase 4 Inhibitors for the Treatment of COPD*

Graham Sturton, PhD and Mary Fitzgerald, PhD

* From Bayer plc, Pharma Research, Berkshire, UK.

Correspondence to: Graham Sturton, PhD, Bayer plc, Pharma Research, Stoke Court, Stoke Poges, Slough SL2 4LY, Berkshire, United Kingdom; email: graham.sturton.gs{at}bayer.co.uk

Phosphodiesterase 4 (PDE4) is a major cyclic adenosine-3',5'-monophosphate-metabolizing enzyme in immune and inflammatory cells, airway smooth muscle, and pulmonary nerves. Selective inhibitors of this enzyme have been available for a number of years and show a broad spectrum of activity in animal models of COPD and asthma. The class-associated side effects, mainly nausea and emesis, appear to have been at least partially overcome by the so-called "second-generation" PDE4 inhibitors. Currently, three companies are in the later stages of development of candidate second-generation PDE4 inhibitors for the treatment of COPD patients. The preclinical profile of one of these, BAY 19–8004, is summarized below. The initial clinical data on the most advanced compound, cilomilast, were indeed encouraging. However, full knowledge of the therapeutic value of this novel compound class awaits the outcome of longer term clinical trials.

Key Words: BAY 19–8004 • cilomilast • COPD • inhibitor • phosphodiesterase • roflumilast • tobacco smoke




This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
B. Hauns, R. Hermann, A. Hunnemeyer, R. Herzog, D. Hauschke, K. Zech, and T. D. Bethke
Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.
J. Clin. Pharmacol., October 1, 2006; 46(10): 1146 - 1153.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
P. J. Barnes
New approaches to COPD
Eur. Respir. Rev., September 1, 2005; 14(94): 2 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. J. Barnes and R. A. Stockley
COPD: current therapeutic interventions and future approaches
Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. G. Smith, F. Wang, K. N. Wilkinson, K. J. Savage, U. Klein, D. S. Neuberg, G. Bollag, M. A. Shipp, and R. C. T. Aguiar
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma
Blood, January 1, 2005; 105(1): 308 - 316.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. D. Murdoch, B. Zussman, J. P. Schofield, and D. M. Webber
Lack of Pharmacokinetic Interactions Between Cilomilast and Theophylline or Smoking in Healthy Volunteers
J. Clin. Pharmacol., September 1, 2004; 44(9): 1046 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Claveau, S. L. Chen, S. O'Keefe, D. M. Zaller, A. Styhler, S. Liu, Z. Huang, D. W. Nicholson, and J. A. Mancini
Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor
J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 752 - 760.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Q. Huai, Y. Liu, S. H. Francis, J. D. Corbin, and H. Ke
Crystal Structures of Phosphodiesterases 4 and 5 in Complex with Inhibitor 3-Isobutyl-1-methylxanthine Suggest a Conformation Determinant of Inhibitor Selectivity
J. Biol. Chem., March 26, 2004; 279(13): 13095 - 13101.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Chest Physicians.